Clinuvel compound improves vitiligo in Phase IIa trial

Clinuvel Pharmaceuticals Ltd. (ASX:CUV; Xetra:UR9) said Scenesse afamelanotide plus narrow-band ultraviolet B (NB-UVB) light met the co-primary endpoints in the Phase IIa CUV102 trial to treat vitiligo. Specifically, four doses of monthly subcutaneous Scenesse plus thrice-weekly NB-UVB light significantly improved pigmentation as measured by Vitiligo Area Scoring Index (VASI) and Vitiligo European Task Force (VETF) scores from baseline to six months vs. NB-UVB alone (p=0.025 and p=0.023, respectively). The open-label, U.S. trial enrolled 41 evaluable patients with generalized vitiligo -- a skin disease characterized by loss of pigmentation. ...